



## Alzheimer's Disease and Mild Cognitive Impairment: Emerging Therapeutic Targets and Treatment Strategies

Guest Editors:

### Dr. Ana Fortuna

1. Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
2. Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, Coimbra, Portugal

### Dr. Miren Ettcheto Arriola

1. Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain
2. Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain
3. Institute of Neuroscience, University of Barcelona, Barcelona, Spain

Deadline for manuscript submissions:

**closed (30 June 2023)**

### Message from the Guest Editors

Dear Colleagues,

Alzheimer's disease (AD) is the most common type of neurodegenerative disorder, characterized by progressive impairment of memory and other cognitive functions. AD is preceded by mild cognitive impairment (MCI), a transitional state between normal aging and AD, which is an early warning signal of the pathology.

The scope of this Special Issue includes the recent advances in therapeutic targets as well as new pharmaceutical formulations and drug delivery systems for the treatment of AD and MCI. We also welcome publications that clarify and update the state-of-art of the mechanisms that underlie both pathologies. Translational investigations from both non-clinical and clinical approaches would be of great significance.

- Alzheimer's disease
- mild cognitive impairment
- pharmacokinetics
- pharmacodynamics
- drug formulations
- brain delivery
- dendritic spines





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma